Genome Editing Market To Reach $10.1 Billion By 2026 | Key Players: Thermo Fisher Scientific, Merck KGaA, GenScript, Horizon Discovery Group and Others

The global Genome Editing market is expected to reach USD 10.1 billion by 2026, according to a new report by Reports and Data. Genome editing refers to a genetic engineering method used for insertion, deletion, or modification in the genome of any organism. Genome editing has come up as promising tool with wide scale application of established genetic engineering technologies such as TALEN and introduction of new methods such as CRISPR technology.

The market is driven by the increasing incidence of genetic diseases, favorable funding scenario for research & development in the field of genetic engineering, technological advancements in genetic engineering such as developments in CRISPR technology, increasing focus of food industry on genetically modified organisms, and rising awareness about efficacy as well applications of genetic engineering methods. For instance, globally over 175 million hectares of land is used for GM crops production. However, stringent regulatory scenario and ethical concerns for gene editing research and applications and concerns among end users regarding use of gene alteration therapies are likely to hinder the market growth during the forecast period.

Request for PDF Sample at: https://www.reportsanddata.com/sample-enquiry-form/1052

Further key findings from the report suggest
CRISPR market is rising at a high growth rate of 30.9 percent in Asia Pacific followed by North America and Europe. Rising application of genetic engineering for therapeutics will drive the demand for the market during forecast period across all regions.

The valuation for TALEN market was USD 1.79 billion in 2018 and is expected to grow to USD 2.01 billion by 2026. Benefits associated with TALEN high degrees of precision and control, is the key factor supporting the wide-scale adoption of the technology and consequently contributing to the market growth.

Asia Pacific is expected to witness a CAGR of 15.8 percent in the forecast period. Emerging markets such China and Japan are likely to witness high growth
Regional regulatory approval is another key regulatory factor for adoption and growth of genetic editing in the region.

Key participants include Thermo Fisher Scientific Inc., Merck KGaA, GenScript, Horizon Discovery Group Plc, Integrated DNA Technologies, Inc, Lonza, New England Biolabs and Sangamo Therapeutics, Inc.

Read more at: https://www.reportsanddata.com/report-detail/genome-editing-market

For the purpose of this report, Reports and Data has segmented the Genetic Editing market on the basis of type, application, end user and region:
Type Outlook (Revenue, USD Million, 2016 - 2026)
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
Transcription Activator-Like Effector Nucleases (TALEN)
Zinc Finger Nucleases (ZFN)
Others

Application Outlook (Revenue, USD Million, 2016 - 2026)
Animal Genetic Engineering
Therapeutic Application
Genetically Modified Organisms
Plant Genetic Engineering
Cell Line Engineering

End User Outlook (Revenue, USD Million, 2016 - 2026)
Pharma-Biotech Companies
Academic Institutes & Research Center
Agrigenomic Companies
Contract Research Organizations

Regional Outlook (Revenue, USD Million, 2016 - 2026)
North America
U.S.
Canada

Europe
Germany
France
U.K.
Spain
Italy
Rest of the Europe

Asia Pacific
China
Japan
India
Southeast Asia

Latin America
Brazil

Middle East & Africa

Make an enqurie at: https://www.reportsanddata.com/make-enquiry-form/1052

We are a boutique market intelligence and strategic consulting firm dedicated to make an meaningful impact on businesses across the globe. Our stellar estimation and forecasting models have earned recognition across majority of the business forum across the globe. Our services are arrayed over diverse sectors and industries looking to expand in alternative regions and products.

40 Wall St. 28th floor New York City, NY 10005 United States

This release was published on openPR.